Context Therapeutics Inc. (NASDAQ:CNTX) Receives $5.40 Consensus Price Target from Analysts

Context Therapeutics Inc. (NASDAQ:CNTX) has received a consensus recommendation of “Buy” from the seven ratings firms that are covering the company, Marketbeat.com reports. Six analysts have rated the stock with a buy recommendation and one has given a strong buy recommendation to the company. The average 1-year price target among brokerages that have issued ratings on the stock in the last year is $5.40.

Several equities analysts have recently issued reports on CNTX shares. D. Boral Capital reiterated a “buy” rating and set a $9.00 target price on shares of Context Therapeutics in a report on Thursday, May 8th. HC Wainwright reiterated a “buy” rating and set a $5.00 price target on shares of Context Therapeutics in a research note on Friday, March 21st. Finally, William Blair reaffirmed an “outperform” rating on shares of Context Therapeutics in a report on Tuesday, April 29th.

Institutional Inflows and Outflows

Several institutional investors have recently made changes to their positions in the business. Jane Street Group LLC acquired a new stake in shares of Context Therapeutics in the fourth quarter valued at about $29,000. Citadel Advisors LLC acquired a new position in shares of Context Therapeutics in the 4th quarter worth approximately $31,000. Shay Capital LLC purchased a new stake in Context Therapeutics during the 4th quarter worth approximately $52,000. Clear Harbor Asset Management LLC increased its stake in Context Therapeutics by 60.6% during the 4th quarter. Clear Harbor Asset Management LLC now owns 57,804 shares of the company’s stock worth $61,000 after buying an additional 21,804 shares during the period. Finally, Landscape Capital Management L.L.C. purchased a new stake in Context Therapeutics during the 4th quarter worth approximately $94,000. Hedge funds and other institutional investors own 14.03% of the company’s stock.

Context Therapeutics Stock Performance

Context Therapeutics stock opened at $0.75 on Tuesday. The stock has a market cap of $67.28 million, a P/E ratio of -0.82 and a beta of 2.11. Context Therapeutics has a fifty-two week low of $0.55 and a fifty-two week high of $2.75. The firm’s fifty day moving average price is $0.78 and its 200-day moving average price is $1.08.

Context Therapeutics (NASDAQ:CNTX) last released its quarterly earnings data on Wednesday, May 14th. The company reported ($0.05) EPS for the quarter, hitting the consensus estimate of ($0.05). Sell-side analysts predict that Context Therapeutics will post -0.51 earnings per share for the current year.

Context Therapeutics Company Profile

Context Therapeutics Inc, a biopharmaceutical company, develops products for the treatment of solid tumors. Its lead program candidate is CTIM-76, an anti-Claudin 6 (CLDN6) x anti-CD3 bispecific antibody that is intended to redirect T-cell-mediated lysis toward malignant cells expressing CLDN6. The company has a collaboration and licensing agreement with Integral Molecular, Inc for the development of a CLDN6 bispecific monoclonal antibody for cancer therapy.